(Q42980354)

12 November 2017

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

7

Michael M C Lai

1 reference

12 November 2017

1

Kung-Chia Young

1 reference

12 November 2017

Ki-Jeong Lee

3

1 reference

12 November 2017

Wen-Chun Liu

4

1 reference

12 November 2017

Jian-Wen He

5

1 reference

12 November 2017

Karen L. Lindsay

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512874

15 March 2024

Susan L. Milstein

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512874

15 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

12 November 2017

http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2003.50445

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

1 reference

12 November 2017

38

1 reference

12 November 2017

869-878

1 reference

12 November 2017

4

1 reference

Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells

12 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

Mechanism of La Crosse virus inhibition by ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

Hepatitis B virus genotypic resistance to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Lassa fever. Effective therapy with ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Respiratory syncytial virus (RSV) disease and prospects for its control

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Studies on the mechanism of the antiviral activity of ribavirin against reovirus.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

RNA virus error catastrophe: direct molecular test by using ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Effect of alpha interferon on the hepatitis C virus replicon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

A reverse-transcription competitive PCR assay based on chemiluminescence hybridization for detection and quantification of hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Quasispecies, error catastrophe, and the antiviral activity of ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840380413

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.1840380413

1 reference

7 January 2021

The New England Journal of Medicine

2

314

20

McCormick

1986

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

4

29

1010

Toltzis

1986

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

The New England Journal of Medicine

15 March 2024

7

339

1485

McHutchison

1998

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

The New England Journal of Medicine

15 March 2024

8

339

1493

Davis

1998

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

Annals of Internal Medicine

15 March 2024

12

132

296

Liang

2000

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

13

33

1668

Fernandez-Larsson

1989

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

14

32

492

Toltzis

1988

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

15

33

2009

Cassidy

1989

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

17

11

946

Eriksson

1977

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

Molecular Pharmacology

19

38

766

Fernandez-Larsson

1990

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

20

6

1375

Crotty

2000

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

Proceedings of the National Academy of Sciences of the United States of America

15 March 2024

21

98

6895

Crotty

2001

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

Annals of Internal Medicine

15 March 2024

28

131

716

Fontaine

1999

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

Proceedings of the National Academy of Sciences of the United States of America

15 March 2024

30

96

13034

Bressanelli

1999

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50445

15 March 2024

Identifiers

10.1002/HEP.1840380413

1 reference

12 November 2017

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14512874

15 March 2024

1 reference